AI Generated by Fortune India
Pharma GCCs contribute $10.5 billion to India's GVA, says OPPI-EY reportNovember 19, 2026, 21:14 IST
Loading AI Hub...
Disclaimer : Certain content on this page, including summaries, timelines, FAQs, glossaries, highlights, insights, and other supplementary informational features, maybe generated or assisted by artificial intelligence tools. While reasonable efforts are made to review and verify such content, AI generated output may occasionally contain errors, omissions or inconsistencies. Readers are advised to independently verify any information before relying upon them for professional, legal, financial, medical or other decisions. The publisher along with its affiliates and contributors do not warrant accuracy of AI-generated content and disclaim any liability, loss or damage arising from its use.

Pharma GCCs contribute $10.5 billion to India's GVA, says OPPI-EY report

/2 min read

ADVERTISEMENT

The report, released at the OPPI’s Annual Summit in New Delhi today, estimates pharma GCCs to employ around 1.2 lakh professionals in India.
Pharma GCCs contribute $10.5 b
Representational image Credits: Sanjay Rawat

The economic contribution of the Global Capacity Centres (GCCs) established by global pharmaceutical majors in India could be as high as $10.5 billion in gross value added (GVA), a report jointly prepared by Organisation of Pharmaceutical Producers of India (OPPI) and consultancy EY estimates.

The report, released at the OPPI’s Annual Summit in New Delhi today, estimates pharma GCCs to employ around 1.2 lakh professionals in India. Separately, the overall GCC sector in India is estimated to have created 10.4 million jobs and 34.9 million sq. ft. of office space in 2025, with a multiplier effect across suppliers, infrastructure, and household consumption.

Sign up for Fortune India's ad-free experience
Enjoy uninterrupted access to premium content and insights.

According to the report, India hosts more than half of the world’s pharma GCC base. Over the years, the GCC model has progressed through four stages, from delivery / cost centre to capability centre, innovation partner and finally enterprise-critical node, it notes. Leading centres now combine specialized domain expertise with data, technology, and enterprise context, and are increasingly measured through defined functional and business outcomes rather than activity volumes alone, the report says.

The new value frontiers for pharma GCCs in India include global ownership for end-to-end capabilities, with decision authority and accountability for end-to-end outcomes; science-to-patient innovation which combines experimental science with India’s digital strength to build integrated lab + AI discovery capabilities; and deeper linkages with hospitals, investigators and clinical infrastructure to position India as a stronger global clinical research hub, the report said. The pharma GCCs can lead to the creation of an India-to-world ecosystem gateway where GCCs connect global biopharma with India’s science, technology, clinical and innovation ecosystem, while giving Indian ideas and capabilities a route into global enterprise networks, it said.

Stating that India already has strong foundations, the report said scaling it further towards these new value frontiers will require coordinated action across GCCs, industry, government and academia to strengthen the talent, technology, scientific infrastructure and operating environment.

The report proposes that the GCCs should build India-based leaders for increasingly global roles, should expand global ownership, decision authority and executive sponsorship and strengthen industry readiness through practical exposure and continuous industry–academia exchange. It calls for strengthening compute and digital infrastructure for increasingly AI-intensive work, strengthening science-led regulatory pathways, Intellectual Property (IP) protection and trusted research-data governance. It wants the government to simplify compliance for increasingly integrated GCCs, align tax and transfer-pricing certainty with evolving mandates and build a coordinated India proposition, supported by effective central and state government facilitation and location readiness.

Follow Fortune IndiaNews, insights and conversations that matter, on your favourite platforms.